End results in central precocious puberty with GnRH analog treatment

The data of the Italian Study Group for Physiopathology of Puberty

F. Antoniazzi, T. Arrigo, M. Cisternino, F. Galluzzi, S. Bertelloni, A. M. Pasquino, P. Borrelli, D. Osio, F. Mengarda, F. De Luca, L. Tato

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We report some end results with GnRH agonist (GnRHa) treatment in central precocious puberty (CPP), in terms of final height (FH), ovarian function, peak bone mass, body composition and psychological problems. The two studies reported (Study I and II) are part of the activity of the Italian Study Group for Physiopathology of Puberty. Study I. Growth data were analyzed of three groups of patients: treated with i.n. spray buserelin, i.m. triptorelin and untreated. Both GnRHa administration modes were effective in arresting pubertal development and all girls had complete recovery of the reproductive axis after therapy. Treated patients showed an improvement in final height in comparison with untreated patients and compared to predicted height at the start of treatment with both agonist treatments. However, patients treated with the long-acting slow release preparation had a better improvement in adult height and reached or exceeded the genetic height potential. Study II. In a retrospective evaluation of the outcome in 71 girls with idiopathic CPP treated with triptorelin, we found that FH fell within the population norm and the target range in 87.3% and 90% of the patients respectively. The tallest FH was recorded in the patients who started therapy at less than 6 years of age and in those who discontinued treatment at a bone age of 12.0-12.5 yr. Finally, we and other groups have recently found normal values of bone mineral density in girls at the end of GnRHa treatment in the great majority of patients.

Original languageEnglish
Pages (from-to)773-780
Number of pages8
JournalJournal of Pediatric Endocrinology and Metabolism
Volume13
Issue numberSUPPL. 1
Publication statusPublished - 2000

Fingerprint

Puberty
Gonadotropin-Releasing Hormone
Triptorelin Pamoate
Therapeutics
Buserelin
Bone and Bones
Health Services Needs and Demand
Central Precocious Puberty
Body Composition
Bone Density
Reference Values
Psychology
Growth

Keywords

  • Bone mineral density
  • Central precocious puberty
  • Final height
  • GnRH agonists

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

Antoniazzi, F., Arrigo, T., Cisternino, M., Galluzzi, F., Bertelloni, S., Pasquino, A. M., ... Tato, L. (2000). End results in central precocious puberty with GnRH analog treatment: The data of the Italian Study Group for Physiopathology of Puberty. Journal of Pediatric Endocrinology and Metabolism, 13(SUPPL. 1), 773-780.

End results in central precocious puberty with GnRH analog treatment : The data of the Italian Study Group for Physiopathology of Puberty. / Antoniazzi, F.; Arrigo, T.; Cisternino, M.; Galluzzi, F.; Bertelloni, S.; Pasquino, A. M.; Borrelli, P.; Osio, D.; Mengarda, F.; De Luca, F.; Tato, L.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 13, No. SUPPL. 1, 2000, p. 773-780.

Research output: Contribution to journalArticle

Antoniazzi, F, Arrigo, T, Cisternino, M, Galluzzi, F, Bertelloni, S, Pasquino, AM, Borrelli, P, Osio, D, Mengarda, F, De Luca, F & Tato, L 2000, 'End results in central precocious puberty with GnRH analog treatment: The data of the Italian Study Group for Physiopathology of Puberty', Journal of Pediatric Endocrinology and Metabolism, vol. 13, no. SUPPL. 1, pp. 773-780.
Antoniazzi, F. ; Arrigo, T. ; Cisternino, M. ; Galluzzi, F. ; Bertelloni, S. ; Pasquino, A. M. ; Borrelli, P. ; Osio, D. ; Mengarda, F. ; De Luca, F. ; Tato, L. / End results in central precocious puberty with GnRH analog treatment : The data of the Italian Study Group for Physiopathology of Puberty. In: Journal of Pediatric Endocrinology and Metabolism. 2000 ; Vol. 13, No. SUPPL. 1. pp. 773-780.
@article{6cd303f040bf4a3888cc2fe2697caa7e,
title = "End results in central precocious puberty with GnRH analog treatment: The data of the Italian Study Group for Physiopathology of Puberty",
abstract = "We report some end results with GnRH agonist (GnRHa) treatment in central precocious puberty (CPP), in terms of final height (FH), ovarian function, peak bone mass, body composition and psychological problems. The two studies reported (Study I and II) are part of the activity of the Italian Study Group for Physiopathology of Puberty. Study I. Growth data were analyzed of three groups of patients: treated with i.n. spray buserelin, i.m. triptorelin and untreated. Both GnRHa administration modes were effective in arresting pubertal development and all girls had complete recovery of the reproductive axis after therapy. Treated patients showed an improvement in final height in comparison with untreated patients and compared to predicted height at the start of treatment with both agonist treatments. However, patients treated with the long-acting slow release preparation had a better improvement in adult height and reached or exceeded the genetic height potential. Study II. In a retrospective evaluation of the outcome in 71 girls with idiopathic CPP treated with triptorelin, we found that FH fell within the population norm and the target range in 87.3{\%} and 90{\%} of the patients respectively. The tallest FH was recorded in the patients who started therapy at less than 6 years of age and in those who discontinued treatment at a bone age of 12.0-12.5 yr. Finally, we and other groups have recently found normal values of bone mineral density in girls at the end of GnRHa treatment in the great majority of patients.",
keywords = "Bone mineral density, Central precocious puberty, Final height, GnRH agonists",
author = "F. Antoniazzi and T. Arrigo and M. Cisternino and F. Galluzzi and S. Bertelloni and Pasquino, {A. M.} and P. Borrelli and D. Osio and F. Mengarda and {De Luca}, F. and L. Tato",
year = "2000",
language = "English",
volume = "13",
pages = "773--780",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - End results in central precocious puberty with GnRH analog treatment

T2 - The data of the Italian Study Group for Physiopathology of Puberty

AU - Antoniazzi, F.

AU - Arrigo, T.

AU - Cisternino, M.

AU - Galluzzi, F.

AU - Bertelloni, S.

AU - Pasquino, A. M.

AU - Borrelli, P.

AU - Osio, D.

AU - Mengarda, F.

AU - De Luca, F.

AU - Tato, L.

PY - 2000

Y1 - 2000

N2 - We report some end results with GnRH agonist (GnRHa) treatment in central precocious puberty (CPP), in terms of final height (FH), ovarian function, peak bone mass, body composition and psychological problems. The two studies reported (Study I and II) are part of the activity of the Italian Study Group for Physiopathology of Puberty. Study I. Growth data were analyzed of three groups of patients: treated with i.n. spray buserelin, i.m. triptorelin and untreated. Both GnRHa administration modes were effective in arresting pubertal development and all girls had complete recovery of the reproductive axis after therapy. Treated patients showed an improvement in final height in comparison with untreated patients and compared to predicted height at the start of treatment with both agonist treatments. However, patients treated with the long-acting slow release preparation had a better improvement in adult height and reached or exceeded the genetic height potential. Study II. In a retrospective evaluation of the outcome in 71 girls with idiopathic CPP treated with triptorelin, we found that FH fell within the population norm and the target range in 87.3% and 90% of the patients respectively. The tallest FH was recorded in the patients who started therapy at less than 6 years of age and in those who discontinued treatment at a bone age of 12.0-12.5 yr. Finally, we and other groups have recently found normal values of bone mineral density in girls at the end of GnRHa treatment in the great majority of patients.

AB - We report some end results with GnRH agonist (GnRHa) treatment in central precocious puberty (CPP), in terms of final height (FH), ovarian function, peak bone mass, body composition and psychological problems. The two studies reported (Study I and II) are part of the activity of the Italian Study Group for Physiopathology of Puberty. Study I. Growth data were analyzed of three groups of patients: treated with i.n. spray buserelin, i.m. triptorelin and untreated. Both GnRHa administration modes were effective in arresting pubertal development and all girls had complete recovery of the reproductive axis after therapy. Treated patients showed an improvement in final height in comparison with untreated patients and compared to predicted height at the start of treatment with both agonist treatments. However, patients treated with the long-acting slow release preparation had a better improvement in adult height and reached or exceeded the genetic height potential. Study II. In a retrospective evaluation of the outcome in 71 girls with idiopathic CPP treated with triptorelin, we found that FH fell within the population norm and the target range in 87.3% and 90% of the patients respectively. The tallest FH was recorded in the patients who started therapy at less than 6 years of age and in those who discontinued treatment at a bone age of 12.0-12.5 yr. Finally, we and other groups have recently found normal values of bone mineral density in girls at the end of GnRHa treatment in the great majority of patients.

KW - Bone mineral density

KW - Central precocious puberty

KW - Final height

KW - GnRH agonists

UR - http://www.scopus.com/inward/record.url?scp=0033858107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033858107&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 773

EP - 780

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - SUPPL. 1

ER -